Rachel Batterham
British physiologist
1 story
1 quote
This study was in patients with Type 2 diabetes, in whom the No. 1 cause of death is cardiovascular disease,
- says Dr. Rachel Batterham, senior vice president of medical innovation and external engagement for cardiometabolic health at LillyTimetime.com/article/2026…
Earlier
Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks
The Independentindependent.co.uk/news/health…Mounjaro affects two of the hormones in the incretin class—GLP-1 and GIP—that have become powerful targets for controlling blood sugar and weight
Timetime.com/article/2026…